Hemostasis in patients with primary myelofibrosis treated with ruxolitinib

Aim. To evaluate the effect of ruxolitinib therapy on hemostasis in patients with primary myelofibrosis (PMF).

Materials and methods. 30 patients with PMF were examined, 16 of them received ruxolitinib (group 1) at the time of examination and 14 were untreated (group 2). The control group consisted of 30 healthy individuals. A complete blood count was performed, the platelets aggregation, the activity of Willebrand factor, factor VIII and natural anticoagulants were evaluated. In the thrombin generation test, the endogenous thrombin potential (ETP, nM×min) was determined; sensitivity to thrombomodulin and coagulation index were calculated. Kruskal-Wallis test with post hoc Dunn test was used to compare groups.

Results. Hemoglobin and platelet count were lower in group 1 compared to group 2 and control. Platelet aggregation with collagen was lower in patients with PMF than in the control group, and lower in group 1 than in group 2: 2.2 (1.6; 5.7) % vs 41.6 (3.4; 64.8) %, p < 0.05. In patients in group 1, the activity of Willebrand factor – 150.0 (122.5; 195) % and factor VIII – 173 (148.5; 200) % was higher (p < 0.05) than in the control: 97 (84.8; 110) % and 104 (85; 130) % respectively. Antithrombin did not differ in the PMF and control group. Protein S was reduced in both groups with PMF: group 1 – 70 (58; 86,6) %, group 2 – 65 (43,6; 107,5) %, control – 102 (86; 109,0) %, p < 0.001. ETP and sensitivity to thrombomodulin in groups 1 and 2 were low, p < 0.001. The coagulation index tended to higher values than in the control: 5.3 (3.0; 11.4) – group 1; 3.2 (2.4; 7.3) – group 2; control – 1.9 (1.6; 2.2), p = 0.073.

Conclusion. Ruxolitinib therapy leads to the failure of the platelet hemostasis, the procoagulant activity of plasma with an increase in the activity of Willebrand factor and factor VIII and a decrease in the activity of protein S.

1. Mahmud M., Vasireddy S., Gowin K., Amaraneni A. Myelo­proliferative neoplasms: contemporary review and molecular landscape. Int J Mol Sci. 2023 Dec 12; 24(24): 17383. https://doi.org/10.3390/ijms242417383. PMID: 38139212

2. Hernández-Boluda J.C., Pastor-Galán I., Arellano-Rodrigo E., et al.; Spanish MPN Group (GEMFIN). Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish registry of myelofibrosis. Br J Haematol. 2022 Nov; 199(4): 529–538. https://doi.org/10.1111/bjh.18440. Epub 2022 Sep 12. PMID: 36089912

3. Papageorgiou L., Elalamy I., Vandreden P., Gerotziafas G.T. Thrombotic and hemorrhagic issues associated with myeloproliferative neoplasms. Clin Appl Thromb Hemost. 2022 Jan-Dec; 28: 10760296221097969. https://doi.org/10.1177/10760296221097969. PMID: 35733370

4. Gangat N., Tefferi A. Myelofibrosis biology and contemporary management. Br J Haematol. 2020 Oct; 191(2): 152–170. https://doi.org/10.1111/bjh.16576. Epub 2020 Mar 20. PMID: 32196650

5. Verstovsek S., Mesa R.A., Livingston R.A., et al. Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety. Journal of Hematology & Oncology. 2023; 16: 82. https://doi.org/10.1186/s13045-023-01471-z. PMID: 37501130

6. Ross D.M., Babon J.J., Tvorogov D., Thomas D. Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications. Haematologica. 2021 May 1; 106(5): 1244–1253. https://doi.org/10.3324/haematol.2020.262691. PMID: 33472356

7. Fisher D.A.C., Miner C.A., Engle E.K., et al. Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling. Leukemia. 2019 Aug; 33(8): 1978–1995. https://doi.org/10.1038/s41375-019-0379-y. Epub 2019 Feb 4. PMID: 30718771

8. Parampalli Yajnanarayana S., Stübig T., Cornez I., et al. JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms. Br J Haematol. 2015 Jun; 169(6): 824–833. https://doi.org/10.1111/bjh.13373. Epub 2015 Mar 30. PMID: 25824483

9. Passamonti F., Harrison C.N., Mesa R.A., et al. Anemia in myelofibrosis: Current and emerging treatment options. Crit Rev Oncol Hematol. 2022 Dec; 180: 103862. https://doi.org/10.1016/j.critrevonc.2022.103862. Epub 2022 Nov 1. PMID: 36332787

10. Vinogradova O.Yu., Pankrashkina M.M., Shikhbabaeva D.I., et al. Possibilities of targeted therapy for myelofibrosis: Moscow experience. Oncohematology. 2022; 17(4): 94–105 (In Russian). https://doi.org/10.17650/1818-8346-2022-17-4-94-105. EDN: SSBTCO

11. Ross D.M., Liang H.P.H., Iqra Z., et al. Platelets from patients with myeloproliferative neoplasms have increased numbers of mitochondria that are hypersensitive to depolarization by thrombin. Sci Rep. 2023 Jun 6; 13(1): 9172. https://doi.org/10.1038/s41598-023-36266-2. PMID: 37280424

12. van Paridon P.C.S., Panova-Noeva M., van Oerle R., et al. Relationships between coagulation factors and thrombin generation in a general population with arterial and venous disease background. Thromb J. 2022 Jun 8; 20(1): 32. https://doi.org/10.1186/s12959-022-00392-0. PMID: 35676710

13. Masciulli A., Ferrari A., Carobbio A., et al. Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis. Blood Adv. 2020 Jan 28; 4(2): 380-386. https://doi.org/10.1182/bloodadvances.2019001158. PMID: 31985808

14. Silina N.N., Korsakova N.E., Golovina O.G., et al. Influence of therapy on the plasma hemostasis in patients with polycythemia vera. MEDLINE.RU. 2020; 21: 75–86. URL: http://medline.ru/public/art/tom21/art7.html (Data publication: 12.02.2020).

15. Matvienko O.Yu., Golovina O.G., Kobylanskaya V.A., et al. Assessment of hemostasis state in patients after new coronavirus infection. Efficiency of anticoagulant profylaxes. Bulletin of Medical Science. 2022; 27(3): 30–36 (In Russian). https://doi.org/10.31684/25418475_2022_3_30. EDN: DUWJNC